Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. - Test2 - elhamkhani - TriplyDB

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

http://www.wikidata.org/entity/Q30542081

about

Procarbazine, lomustine and vincristine for recurrent high-grade glioma Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas External beam radiation dose escalation for high grade glioma High-grade glioma management and response assessment-recent advances and current challenges Current status of biomarker research in neurology Imaging of oligodendroglioma Recent Molecular Advances in Our Understanding of Glioma Clinical management of grade III oligodendroglioma Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods Modern brain tumor imaging Oligodendroglioma: pathology, molecular mechanisms and markers Molecular biology of high-grade gliomas: what should the clinician know?Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs Molecular heterogeneity in glioblastoma: potential clinical implications Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors Neuro-oncology: Five new things.Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.Pros and cons of current brain tumor imaging Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging.The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.[Epilepsy-associated tumors of the central nervous system: Epilepsy surgery and oncological aspects].Detecting tumor progression in glioma: Current standards and new techniques.Recent advances in subtyping tumors of the central nervous system using molecular data.Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors.IDH mutations: genotype-phenotype correlation and prognostic impact.Actionable molecular biomarkers in primary brain tumors.Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.Genetic landscape of extreme responders with anaplastic oligodendroglioma.Does early resection of presumed low-grade glioma improve survival? A clinical perspective.Morphologic spectrum of glial tumors: an increased trend towards oligodendroglial tumors in Pakistan 1p/19q testing has no significance in the workup of glioblastomas.Central nervous system cancers Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.

P2860

Q24187436-A2A9EC18-04D1-4AE5-9E61-5F9C80EBDF35 Q24194645-06B24B52-9B4B-4203-B3F1-7A3BA2428F82 Q26470382-A80CDF16-4549-4225-978B-420E07638C5F Q26740664-257BBA2F-5371-4120-9717-F5ACB7A8EFBE Q26744505-0136DD91-E347-4D60-9DA3-7D31E2F2DD59 Q26768596-F9E2BDCB-B28E-4363-9881-57287FF8A753 Q26798442-EFF30609-5B0D-46C4-B6F5-2D8AF8E61DF3 Q26801254-B5E34E64-30DB-4F10-AFEB-69DF88C61796 Q26853516-3B9C4F1C-864B-47BF-AAFB-162F2EA10315 Q27002344-BE2A2E42-53A0-4075-8602-4E9E9A7E0DC2 Q27002448-465B515A-1220-43CC-A55D-D9F90F6BAC90 Q27009190-89D3B889-71EF-4097-BD4D-D376DFFB6885 Q27310843-45CF16B9-1E2D-470A-B9AC-EE2CC6DDD7B2 Q27853175-1403A8AE-A6E7-44E1-A162-C900C4FC9A86 Q28066926-89B18C16-BB55-4FCE-8177-F27F50F28942 Q28082603-32C1FE15-09B9-4D72-AC3E-D3DA34B0D316 Q28088605-FC3519E3-EC0E-4323-8866-5D8847517C54 Q28383205-1B8A25A2-7578-4352-BDEE-3E26F22A3D07 Q30275188-B965CBEC-0841-4C9E-ADEF-6284B6CE4333 Q30370204-1DB83D4E-113F-41C0-B197-2E55C931AF6B Q30415098-A0599772-2B77-4D12-B7F6-5D69CDFAC026 Q30836702-28593FE1-29E8-40B0-BF2A-CEAC5A4F2C47 Q30860126-65600C22-C089-4131-8CFB-9FA1C5396DEC Q30984368-27759C57-128D-4FFE-98BD-6B1F32C82F3E Q31016193-C91A4DE9-53CC-4093-AEC2-97DA74A13AA5 Q31032523-70548C80-8CC6-4989-8276-6490D2C6BC2A Q31132701-806C4FAF-4DA3-45D9-B1CC-EA106072FF63 Q31145092-8E963744-A574-4D8D-B067-FBDB650C0F2B Q33419628-371A215C-C7F3-4984-8DF7-F658DF4FA905 Q33439379-2F3C07C0-521E-4C2C-8EA3-5D4EC4C78FF7 Q33599587-E6818402-38FD-4673-AF92-0B76C66B2742 Q33615867-EB44F85F-C0BD-4853-B031-DB70F2DA755D Q33772355-E8504EF1-B0B9-4E7A-AA4C-76C77051C69D Q33804713-00856098-3ADA-4580-A77B-7B532A4BD395 Q33829209-ACF00F82-1EAB-4C27-848D-B97D3C659DB5 Q33867304-DDE56D36-E0D0-45AE-A260-21F5AADC42D2 Q33869758-266566CA-3FA6-4328-919D-8853F361C028 Q33893445-0E953551-DEC6-41B4-92FB-C1FD1979FD4F Q34014740-D1632252-F7D3-4A2A-9A3F-73DF35D35D94 Q34062043-7443B995-93EF-4531-9CCE-DDA8D743D305

P2860

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

http://www.wikidata.org/entity/Q30542081

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase III trial of chemoradiot ...... ong-term results of RTOG 9402.

@ast

Phase III trial of chemoradiot ...... ong-term results of RTOG 9402.

@en

type

label

Phase III trial of chemoradiot ...... ong-term results of RTOG 9402.

@ast

Phase III trial of chemoradiot ...... ong-term results of RTOG 9402.

@en

prefLabel

Phase III trial of chemoradiot ...... ong-term results of RTOG 9402.

@ast

Phase III trial of chemoradiot ...... ong-term results of RTOG 9402.

@en

P1433

Q30542081-6E68737D-348A-4177-A978-7A9D4D4BD6F0

P1476

Q30542081-B3AC81F4-7524-4BCB-A945-0B23623F00AD

P2093

Q30542081-0E2DC102-ABC9-479C-ABAA-55BB3FE6C8C0

Q30542081-4ACA0FCF-EAFA-43ED-A917-8DECC6D482EE

Q30542081-7B5A508D-2902-469B-8A49-6779FBFA930B

Q30542081-7BADB4B5-A016-476F-B358-9F616ADBA40C

Q30542081-8DD735C7-A2C2-442F-A3C0-B39CD1683C5B

Q30542081-9F84A34E-C110-45B7-B030-F81D6208FA76

Q30542081-A00C85B0-AAFE-45F2-868F-5E8FFF468896

Q30542081-E16F3AD8-7F28-4079-B7EC-78E5C2D9FD8B

Q30542081-FCEE59AA-941E-465B-B8AC-0AE2A3988546

P2860

Q30542081-06707B40-DAEA-4D92-9537-32597CE0E8C1

Q30542081-14E253B3-618E-4F59-ADDE-C693F287D631

Q30542081-21B80192-CBC4-474F-89E5-270D01044DA7

Q30542081-23905827-E039-4891-B4BA-7136A962549D

Q30542081-249EB61F-126D-4424-A044-1C2CC73D7445

Q30542081-2E543E74-9E5B-41E6-AF9C-1D64CB23AA96

Q30542081-31A59C85-DD9A-4A70-93C5-0AB4E4641F27

Q30542081-33FE06E7-62A0-44B2-9177-6EC3AA10DE46

Q30542081-361EEB9B-5FC8-4711-B951-40EC024D94DB

Q30542081-3F3A9540-0385-4C9C-8BEF-CE3292D700AC

P304

Q30542081-A9735014-C80C-4F8B-9F99-E99908347565

P31

Q30542081-81EA66DE-FAA6-4F1E-8495-6439172B2CC6

P356

Q30542081-8264D057-FFE9-4A6A-A678-6474AFA4FAEB

P407

Q30542081-DEA0089F-579D-404B-8B34-8F34A2085492

P433

Q30542081-31212F60-B2FE-44CE-A07E-0F4726107AF0

P478

Q30542081-37E3AEBA-39DE-4242-9E1D-EA4650229D4B

P50

Q30542081-02154214-48BE-49C1-96D6-DF18B4058E4C

Q30542081-49F5B916-6948-40C7-BA1D-3922E28233FE

P577

Q30542081-F37E9A3B-E51C-402A-8898-2151D284F203

P5875

Q30542081-994F56DB-CCD5-4C8A-BDAD-AC9B2A3418A0

P698

Q30542081-8613C662-1B95-4471-BC81-A8446BE5A4F9

P921

Q30542081-0A496037-BA49-47A4-85E5-0D28090836BD

Q30542081-3F64342F-7F0E-4609-864D-9DA22CAAFDFD

Q30542081-ED494423-CFD5-4F70-8163-42439D55F93C

P932

Q30542081-2CC17101-B3F9-4266-B134-73969182216E

P356

JCO.2012.43.2674

P1433

Journal of Clinical Oncology

P1476

Phase III trial of chemoradiot ...... long-term results of RTOG 9402

@en

P2093

David Brachman

http://www.w3.org/2001/XMLSchema#string

Edward Shaw

http://www.w3.org/2001/XMLSchema#string

Gregory Cairncross

http://www.w3.org/2001/XMLSchema#string

Jan Buckner

http://www.w3.org/2001/XMLSchema#string

Karen Fink

http://www.w3.org/2001/XMLSchema#string

Luis Souhami

http://www.w3.org/2001/XMLSchema#string

Meihua Wang

http://www.w3.org/2001/XMLSchema#string

Robert Jenkins

http://www.w3.org/2001/XMLSchema#string

Walter Curran

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

IDH1 and IDH2 mutations in gliomas

“Mini-mental state”

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Mutations in CIC and FUBP1 contribute to human oligodendroglioma

Malignant gliomas in adults

Initial treatment patterns over time for anaplastic oligodendroglial tumors.

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors

P304

337-343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.43.2674

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Normand J. Laperriere

P577

2012-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232256881

http://www.w3.org/2001/XMLSchema#string

P698

23071247

http://www.w3.org/2001/XMLSchema#string

P921

oligodendroglioma

phase III clinical trial

chemoradiotherapy

P932

3732012

http://www.w3.org/2001/XMLSchema#string